Vertebral Fractures Associated With COVID-19 Severity and Prognosis
Vertebral fractures may be an easily obtained indicator of cardiorespiratory risk and COVID-19 prognosis.
Vertebral fractures may be an easily obtained indicator of cardiorespiratory risk and COVID-19 prognosis.
For patients with six immune-mediated inflammatory diseases, the risk for CVD is increased in association with glucocorticoid dose.
Study authors evaluated the effects of methotrexate discontinuation on influenza vaccine response during the COVID-19 pandemic.
A phase 3 study evaluating the efficacy and safety of ruxolitinib for the treatment of COVID-19 did not meet its primary end point.
Researchers evaluated the effectiveness of hydroxychloroquine for the prevention of COVID-19 mortality in patients with rheumatologic disease.
More than one-third of children with a positive result for SARS-Cov-2 are asymptomatic.
Researchers evaluated the clinical effect of baricitinib on mortality and morbidity in patients with COVID-19.
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.
The ORCHID trial was halted in June 2020 after it was determined that hydroxychloroquine was unlikely to benefit hospitalized patients.